Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.


Founders Jean-Franu00e7ois Dehecq Jean-Renu00e9 Sautier


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 20
Average round size
The average size of a deal this fund participated in
Portfolio companies 19
Rounds per year 1.11
Lead investments 7
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 5
Key employees 29

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical

In 2004 was created Sanofi, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Paris. The venture was found in Europe in France.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2019. Comparing to the other companies, this Sanofi performs on 11 percentage points less the average number of lead investments. The increased amount of exits for fund were in 2019. The typical startup value when the investment from Sanofi is 500 millions - 1 billion dollars. The fund is generally included in less than 2 deals every year. Speaking about the real fund results, this Corporate Investor is 25 percentage points more often commits exit comparing to other organizations.

We also calculated 28 valuable employees in our database.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Sanofi, startups are often financed by Third Rock Ventures, Themelios Ventures, Research Corporation Technologies. The meaningful sponsors for the fund in investment in the same round are Casdin Capital, Virginia Tech Carilion (VTC) Innovation Fund, Verily. In the next rounds fund is usually obtained by VT Ventures, Sequoia Capital China, Redmile Group.

The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight BioNtech, Icosavax, Aetion. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Life Science, Pharmaceutical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Sanofi:
Typical Co-investors
Sanofi is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Sanofi:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AEON RETAIL Chiba Prefecture, Japan, Tateyama
Aion Direct Singapore Central, Central Region, Singapore
Alpha Associates Switzerland, Zürich, Zurich
Arz Portfolio Istanbul, Istanbul, Turkey
Context Ventures District of Columbia, United States, Washington
Cork Japan, Tokyo
Dongbu Ziben China, Hangzhou, Zhejiang
FinTech Innovation Lab New York, New York, United States
KPG Ventures -
LinX Corporation California, Carlsbad, United States
Management 360 -
MobiKwik Gurgaon, Haryana, India
Moon Wan Sun Investments -
Nifco England, Stockton-on-Tees, United Kingdom
OnWave Ventures Canada, Oakville, Ontario
Rkylin Group Beijing, Beijing, China
Shanghai Qifeng Investement Management Co.,Ltd. China, Shanghai
Various Boca Raton, Florida, United States
Ying Capital Beijing, Beijing, China

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

xInnovent Biologics

Drug Discovery
$312M04 Aug 2022 Gusu District, Jiangsu, China

Areteia Therapeutics

Health Care
Life Science
$350M12 Jul 2022 -


Artificial Intelligence
Health Care
$100M10 Jan 2022 Oxford, England, United Kingdom


Artificial Intelligence
Clinical Trials
Machine Learning
Other Healthcare Technology Systems
$180M18 Nov 2021 New York, New York, United States

Gyroscope Therapeutics

Health Care
$60M08 Nov 2021 United Kingdom, England, United Kingdom


Artificial Intelligence
Health Care
Information Technology
$2M16 Feb 2021 Auvergne-Rhône-Alpes


Health Care
$51M03 Oct 2019 Seattle, Washington, United States

Veralox Therapeutics

$5M05 Sep 2019 Frederick, Maryland, United States


Artificial Intelligence
Health Care
Life Science
$27M05 Feb 2019 New York, New York, United States


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sanofi?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: